Drugs / BBIBP-CorV vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05249816 Comparator | Mar 2022 → May 2023 | COVID-19 | Cogna Technology Solutions LLC | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBIBP-CorV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05249816 ↗ |
| Modality | Vaccine | “BBIBP-CorV vaccine” NCT05249816 ↗ |
| Route | Intramuscular | “single intramuscular injection” NCT05249816 ↗ |